Bamco Inc. NY Acquires 58,611 Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Bamco Inc. NY raised its holdings in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 13.6% in the third quarter, Holdings Channel reports. The firm owned 489,386 shares of the company’s stock after purchasing an additional 58,611 shares during the period. Bamco Inc. NY’s holdings in Establishment Labs were worth $21,176,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Hood River Capital Management LLC purchased a new stake in Establishment Labs in the 2nd quarter worth about $43,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Establishment Labs during the 3rd quarter valued at about $127,000. Nkcfo LLC bought a new stake in Establishment Labs during the 2nd quarter worth approximately $227,000. SG Americas Securities LLC purchased a new stake in Establishment Labs in the 2nd quarter worth approximately $303,000. Finally, Black Swift Group LLC bought a new position in Establishment Labs in the 3rd quarter valued at $312,000. 72.91% of the stock is owned by hedge funds and other institutional investors.

Establishment Labs Stock Performance

NASDAQ:ESTA opened at $46.00 on Tuesday. The company has a debt-to-equity ratio of 5.94, a quick ratio of 2.29 and a current ratio of 3.62. Establishment Labs Holdings Inc. has a fifty-two week low of $22.05 and a fifty-two week high of $60.12. The firm has a market cap of $1.29 billion, a PE ratio of -17.83 and a beta of 1.20. The business has a 50 day moving average price of $43.31 and a 200-day moving average price of $44.63.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Stephens reaffirmed an “overweight” rating and issued a $68.00 price target on shares of Establishment Labs in a report on Wednesday, August 7th. Citigroup increased their price objective on Establishment Labs from $45.00 to $50.00 and gave the company a “neutral” rating in a research report on Tuesday, October 1st. BTIG Research increased their price target on shares of Establishment Labs from $62.00 to $65.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Establishment Labs from $61.00 to $50.00 and set an “overweight” rating for the company in a report on Wednesday, August 7th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $60.60.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.